Catalyst MedTech Establishes Full Access Neurology Solution for Brain PET Implementation in the U.S.

Why It Matters

By removing financial and staffing barriers, the solution accelerates adoption of advanced neuroimaging, improving early diagnosis and expanding research capabilities. This shift could reshape reimbursement models and intensify competition among imaging vendors.

Key Takeaways

• Catalyst launches Full Access Neurology to scale Brain PET across U.S.
• Solution bundles equipment, service, workflow integration, and flexible deployment.
• Targets Alzheimer’s, Lewy body, frontotemporal dementia, brain tumors, CTE.
• Leverages 26 years of nuclear cardiology deployment expertise.
• Enables in‑house imaging without capital or staffing barriers.

Pulse Analysis

The rise of biomarker‑driven diagnostics has turned brain positron emission tomography (PET) into a cornerstone for early detection of Alzheimer’s disease and other neurodegenerative disorders. Amyloid, tau and FDG tracers now provide clinicians with quantifiable signatures that guide therapeutic eligibility and monitor disease progression. Yet, despite clear clinical value, adoption has lagged because most hospitals lack the capital, specialized staff, and integrated workflows required to operate dedicated brain PET scanners. This gap has created a market inflection point where scalable solutions are in high demand.

Catalyst MedTech’s Full Access Neurology platform tackles those barriers by bundling hardware, service contracts, quantification software and clinical workflow tools into a single, subscription‑style offering. The package includes a dedicated Brain PET system powered by the CareMiBrain suite, nationwide maintenance, and flexible deployment models that let health systems launch imaging sites without upfront equipment purchases or hiring additional technologists. Drawing on more than 26 years of experience scaling nuclear cardiology programs, Catalyst applies a proven ‘equipment‑as‑a‑service’ model to neurology, accelerating rollout while standardizing imaging protocols across disparate facilities.

The broader impact extends to patients, clinicians and research networks. By lowering financial and operational thresholds, more community hospitals can offer amyloid and tau PET scans, shortening the diagnostic pathway for dementia and enabling earlier therapeutic intervention. Standardized data streams also feed multicenter trials, improving statistical power and accelerating drug development. Competitors that rely on traditional capital‑intensive sales will face pressure to adopt similar service models, while insurers may begin to reimburse bundled PET services as a cost‑effective alternative to referral‑center imaging. Catalyst’s approach therefore reshapes the neuroimaging landscape toward greater accessibility and value‑based care.